Discovery on Target
Discovery on Target Mobile Header
Archived Content


Day 1  |  Day 2 

Diabetes Drug Discovery Brochure 

Download Agenda 


Join scientific colleagues for discussions around risks and progress in the field of type 2 diabetes drug discovery and development. From podium presentations, an 'expert' panel session, roundtable breakout discussions and networking opportunities you will be able to:

-Keep abreast of progress on SGLT2 inhibitors and other anti-diabetes drug candidates
-Ask questions of panelists discussing 'Diabetes Drug Development Challenges'
-Learn about gastric by-pass proteins and other new targets for diabetes drugs
-Participate and problem-solve in a small group discussion on a focused topic of interest to you

Please also join us for a special dinner short course* on Targeting Pancreatic Islets for Type 2 Diabetes(click here), one of the newest areas of diabetes research, which takes place on the evening of the first day of the meeting, Nov. 3rd.

*separate registration required

THURSDAY, NOVEMBER 3

 

Diabetes Drug Development from
Different Vantages
 

1:30 pm Chairperson's Remarks

Rebecca Taub, M.D., CEO, Madrigal Pharmaceuticals

 

1:40 FEATURED PRESENTATION:

Inhibiting Glucose Transporters via SGLT inhibitors – the Next New Diabetes Drug Family?

Michael MarkMichael Mark, Ph.D., Vice President, CardioMetabolic Diseases Research, Boehringer Ingelheim

This presentation will provide an update on diabetes drug candidates in late stage development, with a focus on compounds targeting sodium glucose transporters. Current challenges faced in the field of diabetes drug development will also be covered. 

 

2:25 FEATURED PRESENTATION:

Diabetes Drug Targets from Gastric Bypass Surgery

Lee KaplanLee M. Kaplan, M.D., Ph.D., Professor, Harvard Medical School

3:10 Networking Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 A Physician’s Perspective on the Future of Diabetes Treatments

Rohit KulkarniRohit N. Kulkarni, M.D., Ph.D., Associate Professor, Medicine, Harvard Medical School; Investigator, Joslin Diabetes Center

This presentation will discuss the scope of the global diabetes problem and which types of diabetes treatments are most needed from a diabetes physician’s and his patients’ perspective to help provide a relevant context to scientists developing new diabetes treatments.

Sponsored by
Taconic_NEW
4:15 Preclinical Research Models of Diabetes and Their Use in Efficacy Assessment of Therapeutics
David S. Grass, Ph.D., Vice President, Scientific Operations, Taconic
To address the challenges facing the biopharmaceutical industry, Taconic was one of the first to develop and validate a broad, in vivo focused platform, which utilizes cost-efficient mice to comprehensively characterize drug development candidates and/or genetic targets. One of the strengths of this program is the ability to characterize genetic targets and potential therapeutics impacting metabolic disorders.  Specifically, a variety of models exist for diabetes, simulating the disease condition by affecting various glucoregulatory pathways.

4:30 A GLP1 Positive Allosteric Modulators Approach for the Treatment of Type-2 Diabetes

Guillaume Duvey, Ph.D., Group Leader, Medicinal Chemistry, Addex Pharmaceuticals

4:45 Diabetes Market Landscape

Kelly Close, MBA, President, Close Concerns

 

5:15 Panel Discussion: Diabetes Drug Development

Moderator: Rebecca TaubRebecca Taub, M.D., CEO, Madrigal Pharmaceuticals
 

Panelists:

Kelly Close, MBA, President, Close Concerns

Rohit N. Kulkarni, M.D., Ph.D., Associate Professor, Medicine, Harvard Medical School; Investigator, Joslin Diabetes Center

Lee M. Kaplan, M.D., Ph.D., Professor, Harvard Medical School

Cristina Rondinone, Ph.D., Vice President, R&D, Head, Cardiovascular/Metabolic Diseases, MedImmune

 

  • Developing diabetes drugs in Asia – how is it different? Is that the future?
  • What will clinical trials look like five years from now?
  • What is the ideal diabetes treatment regimen?
 

5:45 End of Day


Please also join us for a special dinner short course* on Targeting Pancreatic Islets for Type 2 Diabetes(click here), one of the newest areas of diabetes research, which takes place on the evening of the first day of the meeting, Nov. 3rd.

*separate registration required

 

Day 1  |  Day 2 |  Download Agenda 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Register Today!

Final Agenda Now Available


 PREMIER SPONSOR

Cellecta

Arrow DownCONFERENCE-AT-A-GLANCE

Arrow DownDOWNLOAD 2016 BROCHURE

Arrow OverSHORT COURSES

Arrow OverVIEW ALL SPONSORS

Arrow OverVIEW MEDIA PARTNERS


SPONSORSHIPS & EXHIBITS

The exhibit hall was sold out in 2015, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2016, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com

 

Sponsorship-vid

DOT-Vid-recap 

IPR-Special-Report-Packages  

SEPTEMBER 19 SYMPOSIA:

Next-Generation Histone Deacetylase Inhibitors

Strategies for Tackling Rare Genetic Diseases

Understanding CRISPR: Mechanisms and Applications

Autoimmunity – Small Molecule Approaches

NK Cell-Based Cancer Immunotherapy

Medical Dermatology Therapeutic R&D and Technical Innovation

CONFERENCES

SEPTEMBER 20-21

Targeting Histone Methyltransferases and Demethylases

Targeting the Ubiquitin Proteasome System

Targeting the Microbiome
– Part 1

GPCR-Based Drug Discovery - Part 1

Advances in Gene Editing and Gene Silencing – Part 1

Gene Therapy Breakthroughs

Antibodies Against Membrane Protein Targets – Part 1

Targeting Cardio-Metabolic Diseases

Targeting Ocular Disorders

SEPTEMBER 21-22

Targeting Epigenetic Readers and Chromatin Remodelers

Kinase Inhibitor Discovery

Targeting the Microbiome
– Part 2

GPCR-Based Drug Discovery - Part 2

Advances in Gene Editing and Gene Silencing – Part 2

Translating Cancer Genomics

Antibodies Against Membrane Protein Targets – Part 2

Metabolomics in Drug Discovery

TRAINING SEMINAR: Data Visualization

SHORT COURSES*

Monday, September 19
8:00 - 11:00 am

(SC1) Immunology Basics for Chemists

(SC2) Designing Peptide Therapeutics for Specific PPIs

(SC3) Phenotypic Screening and Chemical Probe Development

(SC4) Medical Dermatology Therapeutic R&D and Technical Innovation - Part 1

Monday, September 19
2:00 - 3:00 pm

(SC5) GPCR Structure-Based Drug Discovery

(SC6) RNA as a Small Molecule Drug Target

(SC7) Using IP Landscape Studies to Improve Your Confidence

(SC8) Medical Dermatology Therapeutic R&D and Technical Innovation - Part 2

Monday, September 19
3:30 - 6:30 pm

(SC9) Targeting of GPCRs with Monoclonal Antibodies

(SC10) Introduction to Targeted Covalent Inhibitors

(SC11) Contact Lens Drug Delivery Systems

(SC12) Introduction to Gene Editing

Monday, September 19
7:00 - 9:30 pm

(SC13) Convergence of Immunotherapy and Epigenetics for Cancer Treatment

Wednesday, September 21
7:00 - 9:30 pm

(SC14) Cancer Metabolism: Pathways, Targets and Clinical Updates

(SC15) Introduction to Allosteric Modulators and Biased Ligands of GPCRs

(SC16) Functional Screening Strategies Using CRISPR and RNAi

(SC17) Challenges and Opportunities in DNA Methyl Transferase (DNMT) Inhibitors as Therapeutics